Western Australia introduces RSV infant immunisation using Beyfortus, reducing hospitalisations by 83%.
Western Australia becomes the first Australian jurisdiction to roll out an infant RSV (Respiratory Syncytial Virus) immunisation. The monoclonal antibody Beyfortus, shown to reduce hospitalisations for RSV-associated infections by 83%, has been used in Europe and the US. The WA government aims to prevent around 700 infant hospitalisations each year. The immunisation, nirsevimab, was approved by the Therapeutic Goods Administration in Australia last year.
March 04, 2024
8 Articles